The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of <= 12 months Journal Article

   

Authors:	Lunning, M. A.; Migliacci, J. C.; Hilden, P.; Devlin, S. M.; Castro-Malaspina, H.; Giralt, S.; Perales, M. A.; Zelenetz, A. D.; Moskowitz, C. H.; Sauter, C. S.
Article Title:	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of <= 12 months
Abstract:	Early relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post-rituximab era. No difference in event-free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of <= 12 months (80% and 42% at 3years, P < 0015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.
Keywords:	survival; doxorubicin; rituximab; cyclophosphamide; vincristine; stem cell transplantation; response criteria; follicular lymphoma; therapy; non-hodgkin lymphoma; stem-cell transplantation; free; non-hodgkin-lymphoma; improves
Journal Title:	British Journal of Haematology
Volume:	173
Issue:	2
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2016-04-01
Start Page:	260
End Page:	264
Language:	English
ACCESSION:	WOS:000374560800008
DOI:	10.1111/bjh.13947
PROVIDER:	wos
PUBMED:	26847389
PMCID:	PMC5051568
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/94776